Sirius XM has quietly become one of the most hated stocks on the market.

Over the past two years, SIRI collapsed from nearly $60 to just above $20. Subscriber growth flatlined. The media dismissed it as “radio in decline.” And most investors walked away without looking back.

But someone else walked in.

Berkshire Hathaway now owns more than 35% of the company.
They just added another 2.3 million shares this spring — a $54 million bet that the market is wrong.

The setup is classic Buffett:

1. A misunderstood business

2. Generating real cash

3. Returning it to shareholders

4. Trading at a deep discount

Today, SIRI trades at just 6–8× forward earnings and 7× free cash flow.
It’s buying back shares. It’s paying a 4.6% dividend. And it’s still embedded in 67% of new cars sold in America.

This is not a growth stock, but it is a cash cow — mispriced by a market that stopped caring.

Valuation and Cash Flow

SiriusXM isn’t trying to be the next Spotify or Netflix.
It doesn’t need to be.

The bull case starts — and mostly ends — with the numbers.

At ~$20/share, SiriusXM trades around 6–8× forward EPS and roughly 7× 2025 free cash flow.
That’s on $1.15 billion in expected FCF this year, rising from $1.0 billion in 2024. By 2027, they’re aiming for $1.5 billion.

This isn’t speculative. The cash is real. It’s recurring. And it’s being returned.

Buybacks: Over the past decade, Sirius has repurchased nearly half its float.
The current $1.17 billion authorization remains active.
Dividends: A $0.27 quarterly payout yields ~4.6% — well above the 10-year Treasury. The payout ratio? Below 40%.

Most media companies are burning cash. Sirius is printing it.

“Free cash flow conversion is expected to reach 44% of EBITDA in 2025.”
That’s margin expansion in a flat-revenue business.

It may not grow fast. But at these multiples, it doesn’t need to grow at all.

Stabilizing Subs: In-Car Is Sticky

This is where the bears get it wrong.

Yes, subscriber numbers have declined.
But under the surface, the trend is improving — and the in-car business is holding strong.

In Q1 2025:

• Net self-pay subscriber losses were 303k, a 16% improvement YoY

• Churn dropped to 1.6%, even after price increases

• Most attrition came from one-time factors: click-to-cancel rules, trial timing, and plan hikes

In other words: the customer base isn’t crumbling. It’s adjusting.

And SiriusXM is adjusting too — by doubling down on the car.

90% of its subscribers use SiriusXM in-car.
That’s where the product is sticky.

Recent moves:

• 360L platform now live in Tesla and Rivian, expanding reach in EVs

• Streaming access for 2M+ Teslas

• Revamped used-car trial program to target secondary buyers

Meanwhile, new modular pricing is opening the funnel:

• $9.99/month “music-only” in-car tier (launched Q1)

• Ad-supported tier coming later this year, designed for price-sensitive users

This isn’t about expanding the TAM — it’s about defending ARPU and keeping churn low.

And the early results say: it’s working.

Cost Discipline and Capital Allocation

When revenue growth is scarce, discipline becomes the edge. SiriusXM knows it.

Over the last two years, they’ve cut $350 million in costs. Now they’re targeting another $200 million in savings by year-end 2025 — trimming low-ROI marketing, cutting non-core bets, and consolidating tech platforms.

This isn’t lip service. The margin impact is real.

Despite flat revenues, adjusted EBITDA is expected to hit ~$2.6B in 2025, only slightly below 2024 levels — because cost cuts are doing the heavy lifting.

Capital allocation remains tight:

• $700M in debt is being paid down this year, dropping net leverage to ~3.6× EBITDA

• Buybacks continue, with over $1.1B still authorized

• The dividend is safe, fully covered by cash flow

Management isn’t chasing growth.
They’re optimizing a cash machine.

In a market obsessed with top-line stories, SiriusXM is quietly compounding on the bottom line. I like growth just as much as anyone, but these deep value plays have worked well for me over the years.

The Catalysts Wall Street Is Missing

SiriusXM isn’t priced like a company with upside.

But there are several levers in motion — and the market has largely stopped paying attention.

First, the long-awaited ad-supported tier is scheduled to launch in the second half of 2025. This opens the door to a large cohort of listeners who’ve historically balked at price — younger users, casual users, and those who already pay for other streaming services. It won’t move the revenue line overnight. But it could begin to reverse the narrative that SiriusXM is priced out of the mainstream.

Second, the Howard Stern contract is up for renegotiation. Stern accounts for a significant portion of paid listening hours, and his renewal (or replacement) will have real implications for retention and content spend. A favorable outcome here — even just stability — would reassure a market that still sees legacy content deals as ticking liabilities.

Then there’s the EV pipeline. Tesla and Rivian integrations are already live, and SiriusXM has been quietly expanding its OEM relationships. The company’s 360L platform makes in-car streaming seamless, even for electric vehicles that don’t include traditional satellite receivers. As EV penetration grows, so does Sirius’s footprint — especially through used-car resales, where SiriusXM continues to embed trial offers.

And finally, the short interest is worth noting. Roughly 10% of the float is sold short — one of the highest levels in a decade. That doesn’t guarantee anything. But it does mean that any positive surprise — a good quarter, a content deal, signs of subscriber stabilization — could force some fast reassessments.

In sum: SiriusXM isn’t dependent on a single breakthrough. But it has a half-dozen quiet catalysts that could stabilize the core business or nudge sentiment in the right direction.

Mispriced, Misunderstood, But Not Missing

This isn’t a high-growth media stock.
It’s a high-margin utility for commuters — and it’s trading like a melting ice cube.

That mismatch is the opportunity.

SiriusXM isn’t trying to reinvent itself. It’s returning capital, cutting costs, defending its in-car stronghold, and adapting its pricing to meet the moment. It doesn’t need subscriber growth to justify the current price — it just needs stability.

At ~7× free cash flow, with a 4.6% dividend and meaningful buybacks, the stock doesn’t need a hero narrative. It just needs to keep doing what it’s doing.

Berkshire’s stake — now over 35% — suggests that’s exactly the bet being made:
No reinvention. No moonshot. Just steady cash flow, patiently compounding, while the market looks the other way. As usual, I’m trading this by selling puts and using the premium to buy the underlying.

SiriusXM isn’t for everyone.
But for value-focused investors, the signal is a lot stronger than the noise.

14 gigawatts of interest.
A reactor that doesn’t need refueling for a decade.
A $3 billion market cap.

That’s the setup. It’s not a moonshot. It’s a bet on electricity demand, execution, and the fact that the U.S. military just picked this company to power a strategic Arctic base.

We’re not betting the farm.
But we are building a position.

This is our first entry into Oklo — a small nuclear company with a big plan: reinvent fission for the 21st century. If they pull it off, they’ll have a head start on one of the most durable problems in modern infrastructure: how to deliver clean, reliable, 24/7 power anywhere it’s needed.

What follows is a breakdown of the tech, the thesis, the risks, and how we’re trading it. Because whether you believe in nuclear or not, power demand is rising — and someone has to supply it.

What Oklo Actually Does

Oklo isn’t trying to rebuild the past. It’s trying to rethink how nuclear works from the ground up — with a compact, self-regulating fission reactor that doesn’t need water, pumps, or even daily supervision.

The company’s flagship design, the Aurora, is a fast-neutron fission reactor. It uses HALEU (high-assay, low-enriched uranium) fuel and circulates heat through liquid metal (sodium), not pressurized water. That choice matters. Unlike the large, complex light-water reactors that make up most of the world’s nuclear fleet, Oklo’s design doesn’t require massive steam turbines, external cooling towers, or human operators on constant watch. It’s small enough to fit on a few acres — and stable enough to run for a decade without refueling public_substack_style.

Each Aurora unit is designed to generate up to 75 megawatts of electricity — or 125 megawatts of thermal energy — with over 90% uptime. And it’s not just the fuel cycle that’s long-lived. The Aurora’s core is built to be sealed and buried, with natural convection and heat pipe-based cooling systems that require no external power to function. It can sit quietly in a remote location, deliver 24/7 baseload power, and shut itself down if something goes wrong — all without operator intervention.

Instead of selling reactors, Oklo plans to build, own, and operate its fleet — selling electricity to customers under long-term contracts. This matters for investors. It turns the company into a future nuclear utility, with recurring revenue tied to 20–30 year power purchase agreements. Not a one-time vendor.

In other words, Oklo isn’t a reactor company. It’s a power company — built on nuclear fission that looks nothing like what came before.

Why It’s Different from the Reactors You’ve Heard Of

When most people hear “nuclear,” they think of disasters. Chernobyl. Three Mile Island. Fukushima. Giant containment domes, spinning turbines, emergency core cooling systems — and human error waiting to happen.

Oklo’s Aurora reactor isn’t just a different model. It’s a fundamentally different design — with physics, fuel, and control systems that make those old risks structurally impossible.

Start with the core. Traditional reactors use water to both cool the fuel and slow down neutrons — which means they run at high pressure, with complex systems of valves and pumps. When one of those fails, or when operators make the wrong call (as they did at Three Mile Island), the system can spiral out of control in minutes.

Aurora doesn’t use water. Its fuel is cooled by liquid metal, and the reactor operates at atmospheric pressure, not hundreds of pounds per square inch. There are no high-pressure steam loops, no massive turbine buildings, and no cooling towers. Just a sealed, passively cooled unit — buried underground — with inherent negative reactivity feedback. If temperatures rise, the reaction slows. If they fall, it picks back up. No operator needs to touch a thing.

Chernobyl failed in part because of a positive void coefficient — a fancy way of saying the reactor got more reactive when things got hot. Aurora is the opposite. Its feedback loops are self-correcting — more like a thermostat than a chain reaction gone rogue.

It’s also small by design. Traditional reactors produce 1,000+ megawatts and require vast infrastructure. Aurora’s 75 MWe footprint is modular and distributed. That’s not just safer — it’s more flexible. Power can be placed closer to where it’s used: data centers, industrial sites, military bases. And each reactor can run for 10 years or more without refueling, which means no complex logistics, no routine shut-downs, and fewer opportunities for anything to go wrong.

There are no analogues in the traditional fleet. This isn’t a scaled-down Three Mile Island. It’s a fundamentally new system — one that removes the most dangerous parts of nuclear before they ever appear.

The Bull Case for OKLO

The bull case isn’t built on vibes. It’s built on numbers — and the numbers are impressive.

Oklo’s disclosed pipeline has grown from under 1 GW in mid-2023 to over 14.1 gigawatts today. That’s a 2,000% increase in just one year . For context, the entire nuclear generating capacity of the United States is about 95 GW. Oklo’s pipeline — if fully realized — would be the equivalent of adding 15% more nuclear capacity to the U.S. grid, using reactors that fit in a parking lot.

Much of this interest is already taking shape as commercial intent. In 2024, Oklo signed a 20-year master agreement with Switch, a data center operator with some of the most demanding uptime and power quality requirements in the industry. That deal alone accounts for 12 GW — nearly 85% of the pipeline. While it's non-binding at this stage, it's a clear signal: customers want Aurora deployed at scale .

And it’s not just Switch. Oklo has also signed:

• A 50 MW deal with Diamondback Energy to power oilfield operations,

• A 100 MW agreement with Wyoming Hyperscale, and

• Letters of intent with Equinix, another major data center provider.

Meanwhile, the Department of Defense awarded Oklo a 30-year contract to deploy a microreactor at Eielson Air Force Base in Alaska. The project is expected to be operational by the early 2030s — and if successful, it opens the door to additional government sites, especially in remote or vulnerable areas .

That’s demand. Now here’s the capacity plan.

Oklo’s first commercial deployment is scheduled for 2027–2028, with plans to scale rapidly thereafter. Their internal projections (from investor materials and public filings) suggest a ramp to several gigawatts in the first five years. If they manage even 25% of the 14.1 GW pipeline by 2032, that implies:

• ~3.5 GW deployed,

• At 90% capacity factor, that’s ~27.5 million megawatt-hours per year,

• At $90/MWh (a conservative PPA price for clean, reliable baseload), that’s $2.5 billion in annual revenue.

And that’s just the base energy sales.

Oklo is also developing fuel recycling capabilities, targeting a long-term reduction in fuel cost by as much as 80%. They recently acquired Atomic Alchemy, a radioisotope producer, for $25 million — giving them potential entry into the $55 billion global isotopes market .

All of this is happening with a market cap around $3–4 billion.

So the math looks something like this:

• ~$3B market cap today

• $2B+ in potential annual revenue within 5–7 years

• 14 GW pipeline

• Government and enterprise customers willing to sign 20–30 year deals

This isn’t a hype stock. It’s a pre-revenue utility with institutional backing and a regulatory tailwind at its back. And the upside, if execution lands, is many multiples from here.

Section 4: The Risks We're Not Ignoring

The upside here is real. But so are the risks. This isn’t a core position. Not yet. And if we’re being honest, there are a few ways this could go sideways.

The biggest one is regulatory. Oklo hasn’t submitted its final license application yet. Their first attempt, back in 2022, got rejected — not because the tech failed, but because the documentation was incomplete. That’s been addressed. But until the NRC signs off, none of this ships. The company says they’ll file by the end of 2025. That’s a hard milestone. If it slips, the entire deployment timeline could move with it.

Then there’s the fuel. Aurora runs on HALEU — a next-generation uranium fuel that’s in short supply. The U.S. is building domestic capacity, and Oklo is well-positioned to be early in line. But if HALEU isn’t available at scale by 2027, no one is flipping the switch.

Execution risk matters too. Oklo’s not just trying to build reactors. It’s trying to stand up an entire vertically integrated power business. That means manufacturing. Siting. Licensing. Financing. Operating. Doing that once is hard. Doing it fifty times in five years is even harder.

The good news? They have the cash to try. After their latest raise, Oklo is sitting on roughly $660 million in liquidity — enough to fund operations through at least 2028, even if revenue takes longer than expected. That’s a bigger cushion than most pre-revenue power startups ever see.

Still, it won’t be enough forever. If the company hits delays — or scales more slowly than planned — it will need to raise again. That’s not a knock, just reality. And in a market that punishes early-stage names on any slip, even a strong long-term story can see its stock cut in half on weak execution.

That’s why we’re treating this like what it is: a venture-stage power company, not a cash-flowing utility. We’re not swinging big out of the gate. We’re sizing for uncertainty — and scaling with proof and milestones.

How We’re Trading It

We’re not just researching Oklo. We’ve started building the position.

We’re tying our entry to something concrete: the company’s first military reactor contract. The Air Force intends to award Oklo a 30-year agreement to build and operate its Aurora reactor at Eielson Air Force Base in Alaska — a landmark deal that validates both the technology and the business model.

This is exactly the kind of milestone we wait for: institutional commitment, long-term cash flow visibility, and a federal partner that doesn’t move casually. It’s not revenue yet. But it’s real.

We’ll continue to build our exposure conservatively — using put premium to fund future entries, scaling as execution plays out. There’s no rush.

You can read the full trade breakdown here:

That’s how far Target has fallen since its 2021 peak — a nearly 65% drawdown that looks, at a glance, like a broken business. But the stock chart doesn’t tell the full story. Because while the market kept selling, the business kept adapting:

1. It fixed its inventory problems.

2. It brought gross margin back to 28%.

3. It scaled digital sales to nearly 20% of total revenue.

4. And it transformed its nearly 2,000 stores into same-day fulfillment hubs — competing not just with Walmart, but Amazon.

This isn’t another department store getting e-commerce’d into irrelevance. Target made it through that war — and came out stronger. Yet the market still prices it like a dying mall anchor.

At today’s levels, you’re buying a $107 billion revenue business for 10.7x earnings — with a 4.5% dividend, $40 billion in owned real estate, and a margin recovery already in motion.

That’s not a speculative bet. It’s a valuation disconnect.

And for investors willing to be patient, that disconnect is the entire opportunity. Especially if you’re building exposure the way I am — using puts, not cash, and stacking ownership over time.

The Setup: Why Target Looks Broken (But Isn’t)

At first glance, the chart tells a simple story: Target peaked at $268.98 in November 2021. Today, it trades around $95 — a 65% drawdown that suggests something broke.

But the market’s narrative doesn’t match the company’s facts.

Yes, Target got hit in 2022. Inflation squeezed consumers, discretionary spending collapsed, and Target’s own inventory missteps forced heavy markdowns. Gross margins dropped to 23.6%, and the stock unraveled.

But since then? Margins have recovered. Inventory is clean. Store traffic is stabilizing. Digital sales are growing again. And operating cash flow last year more than doubled.

Meanwhile, Wall Street hasn’t noticed — or doesn’t care. Target now trades at just 10.7x trailing earnings, well below its 5-year average of 16–18x, and far cheaper than peers like Walmart (~23x) or Costco (~34x).

It’s not priced like a $100 billion revenue business. It’s priced like it’s in terminal decline.

And that’s the disconnect.

Because this isn’t Macy’s. It’s not Bed Bath & Beyond. Target didn’t get Amazon’d. It adapted. Its digital sales now account for nearly 20% of revenue. Nearly every online order gets fulfilled through its store network — lowering cost and boosting speed. Same-day fulfillment (Drive Up, Shipt) now powers more than a third of digital revenue. And its app sits in the pockets of 30 million Americans.

This isn’t a legacy retailer trying to play catch-up. It’s a modern, omnichannel operator that’s already done the work. The results just haven’t shown up in the stock yet.

The Core Business Still Works

This isn’t a company in secular decline. Over the last decade, Target has quietly grown revenue from $71 billion (2014) to $107 billion (2024) — a ~4% CAGR, despite macro headwinds and consumer volatility. Even with inflation-adjusted spending under pressure, the core engine is still running.

Same-store sales (comps) have been volatile, but the pattern isn’t collapse — it’s normalization. After pandemic-era comps surged +19% and +13% in 2020–2021, they fell -3.7% in 2023 as stimulus wore off and discretionary demand dried up. That’s not a broken business — that’s a reversion.

And while the headlines focused on shrinking foot traffic and markdowns, the mix quietly shifted in Target’s favor:

• Essentials and groceries now make up ~50% of total sales — a natural hedge during economic softness.

• Beauty and Food & Beverage comped positive in 2024, helping offset softness in home and electronics.

• Digital sales now account for nearly 20% of total revenue, up from just 5% a decade ago — a clear sign Target didn’t miss the e-commerce wave.

Importantly, margins are coming back.

After dipping to 23.6% gross margin in 2022, Target has recovered to 28.2% in the latest quarter — not far from its pre-pandemic average. Operating margins have also clawed back to 5.3%, and management is guiding for continued improvement in 2025.

That margin trajectory matters. At scale, even a 50–100 basis point improvement in operating margin adds billions in earnings power. If they reach a 6–7% range again — which they did as recently as 2021 — the earnings story flips quickly.

Add to that their ability to control costs — SG&A held flat in 2024 despite inflation — and you get a business that’s more efficient now than during the stimulus boom.

So no, this isn’t a growth rocket. But it’s a wide-moat operator, with a proven omnichannel platform, clean inventory, and a balanced category mix that can absorb consumer cyclicality.

In a world where most retailers are either dying, overstored, or overleveraged, Target stands out for what hasn’t changed — and what quietly has.

Real Assets, Real Value

Most investors see Target as a retailer. But on the balance sheet, it’s also something else: a quiet real estate empire.

Roughly 90% of Target’s stores are owned, not leased — a stark contrast to peers like Macy’s or department store chains that lease most of their footprint. Add in its distribution centers and owned land, and Target controls an estimated 254 million square feet of property.

That’s not just operational flexibility. It’s hard asset value.

Conservative estimates peg Target’s real estate portfolio around $40 billion, or about $60 per share. At today’s ~$95 stock price, that implies the market is only valuing the entire retail operating business at $35 per share.

Let that sink in: The brand, the stores, the digital infrastructure, the $100 billion in annual sales — all of it is being valued like a distressed department store with no future. Meanwhile, Target’s real estate sits there quietly as a built-in margin of safety.

But this isn’t just about what Target owns. It’s about what it generates.

• Operating cash flow: $8.6 billion in 2023

• Free cash flow after capex: $3.8 billion+

• Dividend payout ratio: ~49% of earnings — not stretched

• Dividend yield: ~4.5%, with a 52-year history of consecutive increases

• Net debt/EBITDA: ~1.5x, with an A credit rating

That means the dividend is sustainable, the debt is manageable, and the buyback authorization (currently $8.7B remaining) could easily resume once earnings stabilize.

It’s rare to find a retailer with this combination of cash generation, financial discipline, and unlevered real estate backing. Especially one that trades at just 7x EV/EBITDA, while Walmart trades at ~11x and Costco around ~18x.

The market sees earnings volatility. But the balance sheet says something else: this is a business with staying power — and asset support most retailers would kill for.

Valuation and Scenarios

Target’s current valuation looks like a market that’s priced in failure — or at least stagnation. But the underlying math tells a different story.

Right now, Target trades at:

• 10.7x trailing P/E (based on $8.86 EPS)

• ~11.9x forward P/E (using midpoint FY2025 guidance of ~$8 EPS)

• 7.0x EV/EBITDA

• ~0.53x EV/sales

• ~4.5% dividend yield, with a 49% payout ratio

Let’s translate that into scenarios.

Bear Case

Consumer spending remains weak, comps stay negative, and margins stall near 5%. EPS dips toward $7. The market assigns a depressed 13x P/E.

• Price Target: ~$90

• Downside: ~5%, mitigated by dividend yield

• Rationale: Prolonged inflationary pressure on essentials and continued discretionary softness

Bull Case

Discretionary demand rebounds, comps turn positive, and Target regains operating margin north of 6.5–7%. EPS hits $10+, and the multiple expands toward 16–17x.

• Price Target: $160–170

• Upside: ~65–80% from today’s price

• Rationale: Retail macro turns, inventory and shrink pressures ease, digital and store traffic both improve

Sum-of-the-Parts Reality Check

Even without a retail turnaround, the $40B+ real estate portfolio alone could justify $60/share in asset value. At $95/share, that implies you’re paying just $35 for the entire operating business — a business that’s still producing billions in cash flow and owns its store network.

In short, the downside is bounded by hard assets and cash flows. But the upside — if margins recover and the market rerates — could be 60–80% or more.

That’s exactly the kind of setup that Collateral Compounding is built for.

Why It Fits the Collateral Compounding Playbook

Let’s be honest: Target probably won’t rip tomorrow.

The main risk here isn’t that the business fails — it’s that the market keeps treating it like it already has. We might sit in a sideways range for months. Maybe quarters. This could be a drawn-out accumulation phase — the kind of grind where nothing happens until suddenly everything does.

But that’s exactly why it fits our strategy.

With Collateral Compounding, we’re not relying on price action to do the work. We’re not calling bottoms or waiting for a breakout. We’re getting paid to patiently build long-term exposure using margin capacity, not cash.

Target is the ideal candidate:

• It pays a 4.5% dividend, covered by strong cash flow.

• It trades cheap — meaning put premiums offer attractive yield relative to risk.

• Its downside is anchored by real estate and essential-goods revenue.

• And it’s backed by a brand, an omnichannel platform, and a management team that’s already fixed the biggest problems.

Every time we sell a put on Target, we’re taking the other side of that mispricing. We’re getting paid to accumulate equity in a high-quality business — at prices that reflect none of its long-term strengths.

And if it trades sideways for six months?

Great.

We’ll keep writing puts. We’ll reinvest the premium into stock. We’ll build a full position — slowly, deliberately — while others ignore it. Then when the rerating comes, it’s all upside.

This is what Collateral Compounding is made for: quiet accumulation in overlooked names, while the rest of the market waits for a headline. The disconnect is already here. Our job is to exploit it.

Mispricing Has a Clock. Not a Catalyst.

The market doesn’t need a press release to fix this.

Target doesn’t need a turnaround plan — it already had one. And it worked.

The reason the price hasn’t moved isn’t because the business is broken. It’s because most investors are still looking at the chart instead of the balance sheet. They’re trading headlines. We’re building positions.

This is what accumulation looks like: sideways price, slowly improving fundamentals, and a growing disconnect between what something is worth and what it costs. It’s uncomfortable. It’s quiet. And it’s usually when the best setups take shape.

That’s why we’re not in a hurry. We don’t need a short-term bounce. We just need time. And with the right structure — selling puts, reinvesting premium, compounding into a high-quality name while the market sleeps — we’re using that time to our advantage.

Eventually, value forces recognition. Until then, we’ll keep getting paid to wait.

In just over a decade, Nubank (NU) went from a startup with a purple credit card to one of the largest digital banks on Earth — with 118 million customers, $3.2 billion in quarterly revenue, and net income of $557 million in a single quarter.

That kind of velocity doesn’t happen by accident. It happens when you combine a broken market with a better model — and move faster than anyone else.

Nubank didn’t invent digital banking. But it made it work at scale, in a region where most incumbents are still charging ATM fees and asking people come into branches and personally sign documents to open accounts. What started in Brazil is now unfolding across Mexico and Colombia, with the same signs of dominance: high engagement, low cost, and relentless product expansion.

And yet — despite the size, despite the profit — Nubank is still early. Only a fraction of its users treat it as their primary bank. Only a slice of Latin America has been converted. And only a small share of regional banking profits has shifted online. I live in Latin America. They are behind but will catch up eventually. And the digital players are going to win the market.

That’s the setup. The story isn’t about what Nubank has already done. It’s about how far it can still go — and whether the rest of the market has noticed. (Hint: It has not.)

The Setup: What Makes Nubank Different

In 2013, Nubank launched with a single product: a no-fee purple credit card for Brazilians fed up with paperwork, hidden fees, and branch lines. That one wedge — designed for a narrow slice of the market — cracked open the entire banking sector.

Today, it’s not a product. It’s a platform. Nubank serves 118.6 million customers across Brazil, Mexico, and Colombia, making it one of the largest digital financial institutions on Earth. It’s profitable, still growing >40% YoY, and has done it all without relying on traditional bank infrastructure.

But here’s the part that should make investors pay attention: despite that scale, Nubank is still early. It’s the primary bank for only ~30% of Brazilian adults, and it holds just ~3% of Latin America’s banking profits. Even in its home market — where it’s already the third-largest bank by customer count — the runway is massive.

The strategy is simple, but powerful:

• Win users with no-fee, digitally native financial products

• Use automation and mobile-first UX to keep costs low

• Layer in more services — loans, investing, crypto, insurance — and monetize through credit and engagement

• Replicate the model across other underbanked but smartphone-rich markets

That last part is key. Brazil was a test case. Mexico and Colombia are proving the strategy scales.

Nubank calls it the “infinite game.” But what they’ve actually built is a compounding engine — one where every new customer costs less to serve, every new product deepens engagement, and every year makes the platform more entrenched. Nubank is playing a different game than its peers.

Product Depth: The Platform Approach

Most neobanks build one or two features and try to scale them. Nubank is doing something else entirely.

They’re building a platform — not just to move money, but to manage every layer of your financial life. From simple savings to high-end travel perks, from budgeting tools to mobile service, the goal is clear: make Nubank the central hub for your wallet.

It started with a credit card. Then came NuConta, a free digital checking account with instant PIX transfers, debit functionality, and auto-yield “Caixinhas” savings buckets. From there, Nubank added personal loans, payroll loans, and working capital for small businesses — covering both consumer and SME credit.

That alone would make it a formidable challenger bank. But Nubank didn’t stop.

They acquired Easynvest to launch NuInvest, offering ETFs and self-directed brokerage access. They rolled out Nubank Cripto, enabling trading across 14 digital currencies — and are exploring tokenized government bonds. On the insurance side, they’ve launched fully digital offerings for life, auto, phone, and home — all priced for accessibility and structured with no hidden fees.

High-income customers haven’t been ignored either. Nubank’s Ultravioleta premium card comes with cashback, travel perks, and wealth management features. They’ve added multi-currency accounts via Wise, and even NuViagens, a travel-booking platform built into the app. Most of these products cross-sell into high-yield deposits like CDBs — which, in Brazil, come with deposit insurance — making them a safe haven for capital as well.

Then came the curveball: NuCel, Nubank’s own mobile phone service. It’s prepaid, contract-free, and deeply integrated — with rewards like extra data for savers. That’s not banking. That’s platform gravity.

In total, Nubank launched 45+ new products on their platform — ranging from “Turbo Caixinhas” (with 15% APY in Mexico) to digital coupons for visually impaired users. These aren’t random side bets. They’re hooks. Each new product keeps users on the platform longer, increases revenue per user, and strengthens Nubank’s hold on the daily habits of its customers.

This is what incumbents miss. They don’t just compete with one Nubank product. They compete with all of them — in one app, with one brand, at one-tenth the overhead.

The Monetization Engine

Nubank isn’t just growing fast. It’s monetizing at scale — with some of the strongest unit economics in global fintech. Let’s start with the headline number:

ARPAC (Average Revenue Per Active Customer) reached $11.20/month in Q1 2025, up 23% YoY on an FX-neutral basis.

That figure is impressive on its own — but what matters more is the direction and distribution underneath it.

ARPAC isn’t flat across cohorts. Mature users — those who’ve been with Nubank longer and adopted more products — are already generating ~$26/month, or $312/year. That’s higher than SoFi. These customers are increasingly sticky, use multiple services, and account for a growing share of revenue.

Even if Nubank stopped adding customers (not going to happen), the growth runway available to them just from upselling alone is enormous.

Engagement, CAC, and Cost-to-Serve

High revenue per user only works if you’re not spending too much to get — or keep — those users.

Nubank’s Customer Acquisition Cost (CAC) is low: $5–$7 per new user. For context, many U.S. fintechs pay upwards of $20–$40 via paid search and referral bonuses. Nubank benefits from virality, brand strength, and mobile-first onboarding — it’s become a default choice in Brazil, not a niche product.

That low CAC pairs with a high monthly active rate: 83%+ of users engage with the platform every month — that’s nearly 99M out of 118.6M customers. Most traditional banks would kill for anything close.

And then there’s the clincher: cost-to-serve.

Nubank spends just $0.70–$0.80 per active customer per month to operate the platform.

That covers everything: tech infrastructure, customer service, compliance, and backend operations. It’s a result of scale, automation, and the absence of physical branches. And it feeds directly into margins.

Profitability and Efficiency

Q1 2025 net income came in at $557 million, representing a net margin of 17% on $3.2B in revenue. That margin outpaces peers like SoFi, which posted $71M in net income on similar revenue (SoFi also uses accounting games to front-load their revenue) — and far exceeds cash-burning players like Dave, which lost money on just ~$100M in quarterly revenue.

Nubank’s efficiency ratio — the share of revenue consumed by operating costs — stands at ~25%. That means 75 cents of every dollar earned flows through as gross profit. Traditional banks often operate with efficiency ratios in the 60–70% range. Even the best-run retail banks rarely drop below 50%.

The difference is architectural. Nubank wasn’t retrofitted for digital. It was built for it.

What’s Behind the ARPAC Climb?

The company has multiple levers pushing monetization higher:

• Credit adoption: Interest income is rising as more customers take on personal loans, payroll loans, and grow card balances.

• Non-interest fees: Interchange, insurance premiums, crypto trading spreads, ATM fees, and NuViagens travel revenue all contribute to service income.

• Cross-sell: With 45+ products, the average Nubank customer now holds multiple accounts — deepening wallet share and raising revenue per user.

• Pricing discipline: With ROE exceeding 40% in 2024, Nubank isn’t chasing market share at all costs. It’s monetizing deliberately — and profitably.

And because they already run lean, every dollar of incremental ARPAC flows through at high margin. The platform scales without the overhead that drags on legacy players.

Takeaway

I live in South America. I am watching first hand as fintech players devour the traditional banks. Nubank, MercadoLibre, these are the companies that are going to control banking in Latin America 10 years from now. Nubank is executing. It's already profitable, already scaled, and already transforming how Latin America banks.

It’s built a platform where the unit economics compound: low acquisition costs, high engagement, multiple revenue streams, and a digital foundation that scales without friction. Add to that a massive underbanked population, rising product adoption, and the beginnings of geographic expansion — and you have a growth engine hiding inside a bank charter.

This isn’t SoFi trying to grind its way to profitability in a saturated U.S. market. It’s not Dave scraping interchange fees from gig workers. It’s a real bank — with real customers and real margins.

The risk is Latin America. The market will get upset every now and then when FX losses and political issues impact quarterly results. But I look past those things. I look at the growth story and the margins.

I'm doing weekly options trades on this name, selling puts when Nubank trades at the low end of its range and pouring the premium back into a long position. I'm building my $0 cost long position for as long as I can, each time the market offers me a nice entry.

That’s the trade. And if Nubank keeps executing, it won’t be a trade at all. It’ll be one of the defining growth stories in global fintech and a core part of my portfolio.

If you were watching Archer Aviation ($ACHR) last week, you saw a stock in free fall.

From $12.17 on June 11 to under $10 in just two days — a nearly 20% drop that erased recent gains. At first glance, it looked like something had gone wrong.

But that wasn’t the case. There was no earnings miss. No canceled contracts. No regulatory delays.

Instead, Archer raised $850 million in fresh capital — and the stock repriced accordingly. The selloff wasn’t panic. It was dilution math.

What’s been missed in all this: the company is actually stronger today than it was before the drop. It now has a $2 billion war chest, new global partnerships, and a tailwind from U.S. policy. One of the most important tech investors in the world just bought the dip.

If you’re a long-term investor, this wasn’t a warning sign. It was a buying opportunity disguised as volatility.

Before the Drop: A Surge of Optimism

The selloff didn’t come out of nowhere. In fact, just days before the dip, Archer was hitting new 52-week highs and gaining momentum.

Why? A few clear catalysts had lined up.

First, the White House issued an executive order supporting eVTOL integration — a formal move to accelerate air taxi adoption in the U.S. That’s not just symbolic. It signals that policymakers are ready to write clearer rules and potentially fund infrastructure. For Archer, it shortens the regulatory timeline and validates the entire business model.

Second, analysts took notice. On June 9, HC Wainwright raised their price target on ACHR from $12 to $18, citing the regulatory support and long-term runway. They weren’t alone — 7 out of 8 analysts covering the stock rated it a Buy by mid-June.

Investors responded. Archer’s CEO called the executive order a “seminal moment,” and the stock surged above $12 by June 11.

So when the drop came, it wasn’t because enthusiasm had faded. It was because the company raised money. And that’s where the story turns.

What Triggered the Drop

The sharp decline in Archer’s stock wasn’t random. It was a direct reaction to a capital raise — one that caught the market off guard, even if the rationale made long-term sense.

On June 12, just one day after closing at $11.73, Archer announced it would raise $850 million by selling 85 million new shares at $10 each. That’s about a 15% discount to the prior close.

This is where the reaction starts to make sense.

For existing shareholders, this wasn’t just a headline — it was dilution. When a company issues new shares, your ownership gets spread thinner. You still own the same number of shares, but they now represent a smaller piece of the pie. So the market did what it usually does in this scenario: it repriced the stock closer to the offering price.

By the next day, shares were trading around $10 — a textbook response to a discounted raise of this size. Volume spiked. Traders exited. The stock chart turned red. But nothing had changed in the business itself.

That’s the key point.

This wasn’t a funding crisis. Archer wasn’t scrambling for cash. In fact, the company already had over $600 million on hand. But aviation is capital-intensive, and management saw a window — both in terms of regulatory momentum and investor demand — to shore up the balance sheet ahead of major milestones.

There were other options. They could’ve raised debt. They could’ve done a convertible. They could’ve offered current shareholders the chance to participate. But they went with a straight equity raise, and they priced it attractively enough to bring in institutional buyers quickly.

In doing so, they made a deliberate trade: short-term pressure in exchange for long-term flexibility. And while the market dinged them for it, the fundamentals didn’t worsen. In fact, they arguably improved.

No revenue guidance was cut. No certifications delayed. No partnerships scrapped.

This wasn’t a company in trouble. It was a company preparing to scale.

What Changed (and What Didn’t)

Archer didn’t just sell shares — it added nearly a billion dollars to its war chest. That single move took the company’s cash balance to nearly $2 billion. For an early-stage aerospace firm, that’s not just padding. That’s survival capital.

With that kind of liquidity, Archer now has the flexibility to move through key milestones without going back to the market. FAA certification. Manufacturing scale-up. Infrastructure buildout. All of it costs money — and Archer just bought itself time.

That matters more than people might realize. eVTOL is not a market that rewards hesitation. It’s a race, and having the cash to move forward — confidently and at full speed — is a competitive edge.

More importantly, this wasn’t panic fundraising. The company wasn’t forced to raise at fire-sale levels. They chose to act while the stock was still elevated, sentiment was strong, and institutional demand was there. In doing so, they traded a short-term hit for long-term independence.

They also now have the financial firepower to deliver on their biggest public commitment yet: serving as the official air taxi provider for the 2028 Olympic Games in Los Angeles. That’s no small goal — and missing it would hurt credibility. Now, with the balance sheet fortified, the company can build with fewer detours or distractions.

What didn’t change?

• The tech didn’t break.

• The business model didn’t shift.

• The long-term strategy — and the regulatory backdrop — are both intact.

This was a reset in share price, not in thesis.

What the Smart Money Did

While retail investors were selling into the dip, one major buyer was doing the opposite: ARK Invest stepped in — hard.

On June 13, the same day Archer was trading near its lows, Cathie Wood’s ARK funds bought 3.43 million shares across three ETFs, including ARKK, ARKQ, and ARKX. That’s over $40 million in fresh capital — all added while most of the market was still processing the dilution.

This wasn’t a small top-up or passive rebalancing. It was a clear vote of confidence — and it came when sentiment was weakest.

Why does that matter?

Because ARK isn’t momentum-chasing here. They’ve held a position in ACHR for a while. They understand the tech, the commercialization roadmap, the regulatory hurdles. And they still chose to average down — during a sharp drop — rather than wait for a rebound.

That’s the kind of behavior you expect from investors with a multi-year view. They weren’t reacting to a headline. They were leaning into a fundamental story that just got stronger.

And their buying likely helped stabilize the stock. Volume surged that day, and by the next session, ACHR shares were already bouncing back. The rebound wasn’t driven by a press release or earnings revision — it was driven by buyers with conviction.

So if you’re wondering whether the drop signaled trouble, this was your answer: institutional money in the innovation space saw it as a discount worth taking.

Stronger Today Than Before the Drop

At first glance, it might seem odd to say a company is in better shape after its stock drops nearly 20%. But that’s exactly what happened here.

If we rewind to June 11 — the last close before the offering — here’s what Archer looked like:

• Trading above $12

• Supported by favorable policy news

• Riding a wave of bullish analyst sentiment

• But holding less than $1.2 billion in liquidity — and burning significant capital each quarter

Compare that to the post-raise position. As of mid-June, the fundamentals are meaningfully stronger across multiple dimensions:

1. A Fortress Balance Sheet

The $850 million raise brought Archer’s total cash to nearly $2 billion. That’s not just a cushion — it’s a full runway.

This new capital gives Archer the ability to:

• Ramp up U.S. manufacturing without delay

• Execute its “Midnight” production schedule

• Build out vertiport infrastructure where needed

• Sustain operating expenses into the back half of the decade

And crucially: it lowers capital risk. Prior to the raise, even bullish investors acknowledged that Archer would likely need to tap markets again before reaching commercialization. That concern is now off the table — or at the very least, pushed far enough out that it no longer affects short-term valuation.

If this were a pre-revenue biotech, this would be the equivalent of funding through FDA approval. In a capital-hungry industry like eVTOL aviation, securing funding before you need it is a strategic edge, not a cost.

2. Policy Tailwinds Just Kicked In

One of the biggest unknowns in the eVTOL space has always been regulatory timing. Will the FAA move fast enough? Will public infrastructure be ready? Will government agencies even take this seriously?

As of early June, those questions got a clearer answer.

The White House issued an executive order to formally launch an eVTOL integration pilot program, aimed at accelerating air taxi deployment in the U.S. While the market focused on the capital raise, this was arguably the more significant catalyst for the company’s long-term outlook.

Archer’s CEO called the order “a seminal moment” — and for good reason. It means:

• The FAA is now working on air taxi rulemaking with explicit federal backing

• Pilot cities and corridors could be established more quickly

• Public-private cooperation will likely expand

This doesn’t eliminate all risk. But it does mark a shift in tone — from “wait and see” to “let’s make this happen.”

And Archer is well-positioned to benefit, especially given its prior deals with United Airlines, its selection as the official air taxi for the 2028 Olympics, and its lead in certification readiness.

3. Global Commercial Traction Is Building

Just days after the capital raise, Archer announced its third international “Launch Edition” partnership — this time in Indonesia.

Under the deal, PT IKN Nusantara will purchase up to 50 Midnight aircraft, worth an estimated $250 million, to deploy air taxi service in Indonesia’s new smart city capital project. This follows earlier agreements in:

• The UAE, through a partnership with Abu Dhabi Aviation

• Ethiopia, with Ethiopian Airlines as the regional operator

These aren’t just paper MOUs. They’re early demand signals — tangible expressions of interest in deploying Midnight aircraft at scale.

For an investor trying to gauge whether this technology will find real-world demand, this is the answer. These agreements build Archer’s order book, give it international visibility, and potentially create network effects as early adopters generate proof-of-concept.

It’s also an important hedge: if FAA certification takes longer than expected, these international routes may go live sooner — creating commercial revenue ahead of U.S. deployment.

4. Analyst Support Remains Firm

You’d expect a big equity raise — especially one priced below market — to rattle the analyst community. But that’s not what happened.

Post-raise, most analysts either held their targets steady or made minor adjustments:

• Canaccord Genuity reaffirmed its “Buy” rating and lowered its target just slightly, from $13.50 to $13 — a modest change given the dilution

• HC Wainwright actually raised its target to $18 just days earlier, based on policy momentum and long-term upside

• As of mid-June, 7 out of 8 analysts covering ACHR rate it a Buy

And perhaps most telling: no major firm downgraded the stock after the raise.

That tells you one thing — Wall Street understands what Archer did and why. And more importantly, they’re not treating the dilution as a sign of weakness.

They see the raise for what it was: a strategic investment in execution capacity. Not a bailout. Not a delay. A setup for growth.

Bottom line: If you’re only watching the share price, it’s easy to think something broke. But zoom out, and Archer’s positioning — both financially and strategically — looks better than it did before the drop.

More cash.
More policy support.
More global partners.
Still backed by analysts.

That’s not deterioration. That’s progress — wrapped in a volatile chart.

Was the Drop Justified or Just Noise?

Let’s be clear — the drop in ACHR’s stock wasn’t irrational.

When a company issues 85 million new shares at $10, the math changes. Dilution means existing shareholders now own a smaller piece of the pie. If the market cap stays the same but the share count goes up, price per share adjusts downward. That’s not panic. That’s algebra.

The market saw the offering price — $10 — and brought the stock down to match it. That’s how price discovery works.

But here’s what matters: this was a one-time adjustment — not a shift in fundamentals. And that’s where the opportunity lies. The company is now:

• Fully funded through its next phase of growth

• Backed by favorable policy momentum

• Expanding internationally, even before FAA certification

• Endorsed — at scale — by ARK Invest and most major analysts

If you believed in the business on June 11 at $12.17, you should believe in it more at $10. And if you didn’t own it then, you’ve now been handed a better entry.

For us, this wasn’t a red flag. It was a gift — and we’re going to take it.

We don’t often get second chances to enter high-conviction names at better terms — especially after fundamentals have improved. But every once in a while, the market gives you one.

When that happens, you don’t ask twice.

You run with it.

That’s what I’m doing. I’m not just watching from the sidelines.

Today, I sold the ACHR October 2025 $9 put for $1.31 — a trade that gives me a wide buffer and a clear path to entry if the stock pulls back again.

I walk through the full setup and mechanics in the trade alert — but the thesis is simple: the stock is cheaper, the business is stronger, and I’m getting paid to take the other side of a temporary repricing.

Regeneron Pharmaceuticals (regn) Comprehensive Investment Analysis

723KB ∙ PDF file

Download

Download

At its core, the report makes a bullish case: Regeneron is undervalued, underappreciated, and entering the next phase of its growth story. Its current valuation (≈13× forward earnings) doesn’t reflect the strength of its cash flows, the durability of its flagship immunology drug (Dupixent), or the size of the upside embedded in its late-stage pipeline. The authors believed REGN has 40% upside from here—with a bull case stretching as high as 70%.

But this isn’t just a momentum play or a "story stock." The bear case gets a full airing too. The company’s leading ophthalmology product (Eylea) is facing a slow-motion patent cliff. Competition is rising across its portfolio. And any stumbles in the pipeline—especially Dupixent's COPD data or its new oncology entrants—could capsize the growth narrative.

This piece walks through both sides of that thesis, with an eye to what’s already priced in, what still needs to go right, and how much risk remains if it doesn’t. I’ll explain where the upside could come from, how durable the existing business really is, and why the stock’s risk-reward profile may look better today than it did even a year ago.

As an uncovered option seller, I’m always looking at risk and downside first. That means studying the bear thesis before even thinking about upside. Many times when I’m selling volatility, I don’t care of the stock does well, especially in the short term. I just need to make sure it won’t fall of a cliff in the next 45-60 days. Let’s get into it and look at the report’s bear thesis:

Bear Thesis: What Was Supposed to Go Wrong — and What Actually Did

The bear case for Regeneron outlined five major risks. Some of them came true. Some didn’t. A few ended up flipping into outright positives. Here’s a breakdown of what was predicted, and where things actually stand.

1. Eylea Patent Cliff

Prediction: Regeneron’s flagship eye drug would face early biosimilar competition. The base case assumed a ~60% collapse in U.S. sales by 2026.

Reality: That cliff arrived early. Amgen launched its biosimilar in late 2024 after Regeneron lost a key injunction, and another biosimilar is set to follow in 2026. Sales have already taken a hit: standard-dose U.S. Eylea revenue fell 39% year-over-year in Q1 2025. High-dose Eylea is helping cushion the blow, but not enough to offset it entirely. The decline is happening fast — and mostly in line with the bear thesis. The key difference? This wasn’t a surprise. Investors saw it coming. Much of that downside now looks “priced in.”

2. Dupixent in COPD

Prediction: The expansion into chronic obstructive pulmonary disease (COPD) would flop — either on weak data or safety concerns — wiping out billions in future sales.

Reality: This one flipped completely. Dupixent became the first biologic ever approved for COPD in 2024. The data were strong, the label was clean, and the commercial potential is big. Analysts now expect ~$3.5 billion in new annual revenue from COPD alone. Instead of shrinking, Dupixent’s growth story got stronger. This removed a massive piece of the bear case.

3. New Competition in Atopic Dermatitis

Prediction: Lilly’s lebrikizumab would eat into Dupixent’s lead in eczema, pulling growth down to single digits by 2025.

Reality: Lebrikizumab is on the market (as Ebglyss), but it hasn’t moved the needle much. Dupixent still dominates and is growing at nearly 20% year-over-year. Ebglyss has a more convenient dosing schedule, and might slowly gain share, but it’s not disrupting the franchise. The bear case overestimated the competitive threat — at least so far.

4. Odronextamab Setback

Prediction: Odronextamab, Regeneron’s bispecific antibody for lymphoma, would get delayed or derailed — giving competitors like Roche and AbbVie a head start.

Reality: This one hit. The FDA rejected odronextamab’s initial application in 2024, citing the need for more data. Rivals are already on the market, and doctors are gaining comfort with those options. Regeneron is now playing catch-up. Approval is still possible (the drug is already approved in Europe), but the commercial window has narrowed. This leg of the bear thesis has largely played out.

5. Fianlimab Failure in Melanoma

Prediction: Regeneron’s LAG-3 antibody combo with Libtayo wouldn’t work — removing a key potential growth driver in melanoma.

Reality: Still TBD. Early data looked strong. But the Phase 3 readout has slipped into the back half of 2025, and the competitive field has moved forward. Even if the combo works, Regeneron will be a late entrant. So while there’s no evidence of failure, the best-case scenario is now a smaller piece of the pie. The risk is still live, but diminished.

Bull Thesis: What Was Supposed to Go Right And Where We Stand Now

When I first got handed this report, the bullish thesis for Regeneron was a classic multi-engine growth story. Dupixent would keep expanding into new indications. Eylea would decline, but gently. A deep pipeline would begin delivering. There was even a hope that a new class of assets — bispecifics, RNAi combos, LAG-3 immunotherapy — might each contribute hundreds of millions in new revenue.

Some of that has happened. Some hasn’t. Here’s a breakdown of what the bull case was at the time, and where things stand today, mid-2025.

Dupixent Expands into COPD — and It Works

Prediction: If Dupixent could replicate its success in asthma and eczema in COPD — a much larger, underserved market — it could easily add $3 billion in new revenue. That would extend its growth runway into the next decade, making it the most successful IL-4/IL-13 drug in history.

Reality: This is one of the cleanest wins for the bull case. In late 2024, the FDA approved Dupixent for COPD with type 2 inflammation — the first biologic ever approved for the condition. This wasn’t a token win either. The Phase 3 data was strong: a 30% reduction in exacerbations, good tolerability, and no black-box warnings.

Commercial uptake is early, but it’s happening. Pulmonologists have been slower to adopt biologics than dermatologists or allergists, but that’s changing. And unlike prior Dupixent launches, there’s almost no direct competition here. If sales follow the same curve as in asthma, this becomes a major new leg for the franchise.

Verdict: Core part of the bull thesis — and now confirmed. Execution is still key, but the thesis was right. This is the reason to consider a new position in Regeneron.

High-Dose Eylea Cushions the Patent Cliff — Or Not

Prediction: Regeneron would steer through the patent expiry on Eylea by pushing adoption of its new high-dose formulation. The base case assumed biosimilars wouldn’t launch until 2027 and that the company could retain much of its ~$5.9B U.S. Eylea business with less price pressure.

Reality: That didn’t play out. Amgen’s biosimilar launched in 2024 after Regeneron failed to block it in court. Another biosimilar is likely coming in 2026. Meanwhile, Q1 2025 data shows standard-dose U.S. Eylea revenue down 39% year-over-year. High-dose adoption has been slower than hoped — and not enough to offset the base erosion.

Investors knew this was coming, so some of the pain is already priced in. But it doesn’t change the fact that Eylea is now a shrinking asset, not a stabilizer.

Verdict: This leg of the bull case broke. Eylea is no longer a bridge to new growth — it’s a headwind.

Odronextamab and the Bispecifics Franchise

Prediction: Odronextamab — Regeneron’s CD20xCD3 bispecific antibody — would emerge as best-in-class for B-cell lymphomas. Approval in FL and DLBCL would unlock a $1B+ market, and Regeneron could leapfrog earlier entrants like Roche’s Lunsumio or AbbVie’s Epkinly.

Reality: The data was decent but not a breakout. Worse, the FDA issued a CRL (Complete Response Letter) in 2024 asking for longer follow-up. That put Regeneron behind competitors who are already on the market and gaining traction. Odronextamab might still get approved later this year — and Regeneron is the only player with data in both FL and DLBCL — but it’s clearly no longer a “category winner.”

Verdict: Still viable, but the market leadership angle is gone. At best, this becomes a supporting player, not a franchise.

Fianlimab + Libtayo: A Shot at the LAG-3 Class

Prediction: Regeneron’s LAG-3 antibody (fianlimab), when paired with its PD-1 drug Libtayo, could compete directly with BMS’s Opdualag in melanoma. If the combo hit its endpoints, it could establish Regeneron in the next wave of immuno-oncology.

Reality: The data so far is promising — strong overall response rates and progression-free survival. But the Phase 3 trial slipped into late 2025, pushing out the timeline. Meanwhile, Opdualag is entrenched and Merck is advancing its own LAG-3 combo. Even if Regeneron succeeds, it’ll be a second- or third-to-market entrant.

Still, the science is sound, and Regeneron has shown it can commercialize Libtayo effectively. A positive readout would give them a viable position in a meaningful oncology segment.

Verdict: A live option. Execution and timing will determine how valuable it becomes.

Pozelimab + Cemdisiran: A Rare Disease Wedge

Predition: By combining an RNAi agent with a monoclonal antibody, Regeneron could offer a novel treatment for PNH (a rare blood disease), potentially leapfrogging Alexion’s Soliris/Ultomiris franchise. If successful, it could validate Regeneron’s platform strategy and open doors to broader RNAi use.

Reality: The Phase 3 data was solid. No major safety concerns. The combo works — and may offer some dosing and tolerability advantages. Approval could come in 2026, and commercial runway exists (PNH is a ~$5B market globally). It’s a small niche, but an important one — especially because it’s Regeneron’s first real RNAi + antibody asset.

Verdict: Undervalued part of the bull case. The science is ahead of the stock price here.

“Smart” M&A with a $17B War Chest

Predition: Regeneron would deploy its massive cash position on smart acquisitions — not speculative moonshots, but near-term growth assets that could plug in fast.

Reality: The company has stayed active, but cautious. It bought Decibel Therapeutics for a gene therapy program, partnered with 23andMe for access to genetic data, and picked up a GLP-1/GIP dual agonist program. All early-stage bets. Nothing accretive in the short term. These may pay off down the road, but for now they’re R&D — not revenue.

Verdict: There is still some potential. But the market was hoping for something more tangible by now.

A Return to Growth — Eventually

Prediction: Even with Eylea in decline, Dupixent plus pipeline assets would return Regeneron to mid-teens top-line growth. With gross margins >80% and lean SG&A, earnings would scale quickly.

Reality: Not yet. Q1 2025 revenues were down year-over-year. Dupixent is growing ~20%, but that’s not enough to plug the Eylea gap — at least not yet. Management expects growth to reaccelerate in 2026 as Dupixent’s COPD launch scales and new approvals (like odronextamab) come online.

Verdict: Delayed, not derailed. But the window to deliver is getting narrower. It won’t happen this year.

Valuation Re-Rating — Still Waiting

Prediction: If growth resumed and the pipeline delivered, REGN’s P/E would re-rate to 18–20x — more in line with peers like Vertex or even Eli Lilly.

Reality: The market hasn’t moved. REGN still trades around 12x forward earnings, partly because of the Eylea overhang and pipeline delays. But if management can string together a few good quarters and COPD uptake accelerates, a re-rating is still plausible.

Verdict: The market wants proof — but the setup is there. It won’t happen this year.

My Take: Most of the Damage Is Done — But the Upside Isn’t

By mid-2025, the core of the bear thesis on Regeneron has already played out. The Eylea patent cliff came earlier than hoped and hit harder than bulls expected. Standard-dose revenue is falling fast, high-dose uptake has underwhelmed, and biosimilars are now a present-tense reality. On the pipeline side, odronextamab was delayed, not denied, and while the setback stung, it didn’t collapse the platform. The competitive threat to Dupixent in eczema turned out to be more noise than signal. The market has absorbed these blows — and Regeneron’s valuation reflects it.

That’s what makes the current setup interesting. The bad news isn’t hiding. It’s already all priced in.

At the same time, key elements of the bull case remain alive — and potentially transformative if they deliver over the next 6–18 months:

• COPD approval for Dupixent is a confirmed win. It’s the first biologic ever approved for this indication, and while uptake is early, the market size is large and the competitive landscape is wide open. This isn’t speculative anymore — it’s an execution story.

• Fianlimab (LAG-3) remains a real shot on goal. The Phase 3 readout is expected in late 2025. If it hits, Regeneron can credibly compete with BMS’s Opdualag in melanoma, opening a new immuno-oncology franchise around Libtayo.

• Pozelimab + Cemdisiran in PNH has real scientific edge. The Phase 3 data was clean. The combo showcases Regeneron’s RNAi + antibody approach, and if approved in 2026, could generate meaningful revenue in a rare disease space with limited competition.

• Growth reacceleration could begin in 2026. With Eylea declines front-loaded and Dupixent expanding into COPD, the company may return to mid-teens revenue growth next year. Margins remain excellent, and the operating structure is built for scalability.

• Valuation remains undemanding. REGN is still trading around 12× forward earnings — far below peers with similar pipelines and better-than-average balance sheets. Even modest execution could support a rerating toward 15×–18×, especially if Dupixent sales begin to outpace Eylea erosion.

That brings us to positioning.

My Trade: Short REGN Puts

At this price level — with sentiment beaten down, the major bearish risks already surfaced, and bullish drivers still live — the risk/reward skews positively for put sellers. The business remains highly profitable and cash-rich. It’s not a turnaround bet. It’s a temporary growth pause in a high-margin innovator.

If you're comfortable owning the stock at lower levels, selling puts at or slightly below current support offers a way to get paid while waiting for the pipeline to resolve. Even if the bullish outcomes take longer than expected — or don’t fully materialize — much of the downside already appears priced in. And if COPD uptake accelerates or the PNH or LAG-3 programs surprise to the upside, you’re positioned to benefit.

Put simply: the bear case is largely behind us. The bull case is still ahead. And the market is paying you to wait.

This isn’t a momentum trade. It’s a valuation + pipeline setup with a defined floor. If you're looking for asymmetric return profiles in biotech, this one deserves a place on the list.